Discover Protalix BioTherapeutics' Q4 2024 earnings insights, including record revenues, pipeline advancements, and future growth prospects.

Protalix Biotherapeutics Inc（纳斯达克股票代码：PLX）发布2024年第四季度财报，总收入同比增长31%。尽管净利润有所下降，但公司创新产品线和战略合作伙伴关系增强了投资者信心，盘前股价上涨7.14%至$2.40。

Newsweek explored the reasons with a LGBTQ+ relationship expert and a woman who made the switch to a same-sex relationship.

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...

Margin Call. He began his career at The Sunday Telegraph and has won multiple awards for crime writing and specialist investigations. In 2014 he was seconded on a year-long exchange to The Wall Street ...

Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...

100 x 80 cm. (39.4 x 31.5 in.) ...

ToI tours IDF's highest army post in Syria, overlooking Damascus and Hezbollah's Beqaa Valley stronghold in Lebanon; Syrian ...

Highlights: Trek through Chunjian’s tea-themed educational park to Bashan’s undulating plantations, featured in The Hunting ...

Announcement comes as Israeli politicians lambast Syrian transitional government for reported mass killings, urge European ...

House of David on Prime Video dives into biblical lore, revealing Goliath’s giant brothers and exploring the world of giants ...